{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:36Z","timestamp":1788984816228,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01865-0","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:24:05Z","timestamp":1785421445000},"page":"4617-4630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from\u00a0the\u00a0Real-World MEASURE-AD Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tanizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"1","key":"1865_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190(1):55\u201361.","journal-title":"Br J Dermatol"},{"key":"1865_CR2","doi-asserted-by":"publisher","first-page":"204062232110667","DOI":"10.1177\/20406223211066728","volume":"13","author":"G Girolomoni","year":"2022","unstructured":"Girolomoni G, Busa VM. Flare management in atopic dermatitis: from definition to treatment. Ther Adv Chronic Dis. 2022;13:20406223211066730.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"1865_CR3","first-page":"587","volume":"29","author":"J Jeskey","year":"2024","unstructured":"Jeskey J, Kurien C, Blunk H, et al. Atopic dermatitis: a review of diagnosis and treatment. J Pediatr Pharmacol Ther. 2024;29(6):587\u2013603.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"1865_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"24","key":"1865_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"1S","key":"1865_CR6","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1097\/DER.0000000000000715","volume":"32","author":"W Smith Begolka","year":"2021","unstructured":"Smith Begolka W, Chovatiya R, Thibau IJ, Silverberg JI. Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States. Dermatitis. 2021;32(1S):S62\u201370.","journal-title":"Dermatitis"},{"issue":"2","key":"1865_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/jdv.19500","volume":"38","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1865_CR8","first-page":"69","volume":"28","author":"X Wang","year":"2022","unstructured":"Wang X, Boytsov NN, Gorritz M, Malatestinic WN, Goldblum OM, Wade RL. US health care utilization and costs in adult patients with atopic dermatitis by disease severity. J Manag Care Spec Pharm. 2022;28(1):69\u201377.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1865_CR9","first-page":"51","volume":"18","author":"G Martin","year":"2025","unstructured":"Martin G, Aldredge L, DiRuggiero D, Young M, Simpson E. An overview of atopic dermatitis disease burden, pathogenesis, and the current treatment landscape: recommendations for appropriate utilization of systemic therapies. J Clin Aesthet Dermatol. 2025;18(3):51\u201366.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"1865_CR10","doi-asserted-by":"publisher","first-page":"e13899","DOI":"10.1111\/cts.13899","volume":"17","author":"MR McCann","year":"2024","unstructured":"McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA. Dupilumab: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e13899.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1865_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927\u201340.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1865_CR12","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1865_CR13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s13555-025-01469-0","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Gooderham M, Wollenberg A, et al. Impact of achieving optimal treatment targets and minimal disease activity on health-related quality of life and satisfaction in patients with atopic dermatitis. Dermatol Ther (Heidelb). 2025;15(8):2255\u201373.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1865_CR14","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s13555-026-01683-4","volume":"16","author":"FJ Melgosa Ramos","year":"2026","unstructured":"Melgosa Ramos FJ, Guillen Climent S, Galarreta Pascual M, et al. Minimal disease activity as a therapeutic goal in atopic dermatitis: predictive factors of sustainability in a multicenter cohort. Dermatol Ther (Heidelb). 2026;16(4):2213\u20138.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1865_CR15","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","volume":"149","author":"HC Williams","year":"2022","unstructured":"Williams HC, Schmitt J, Thomas KS, et al. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1899\u2013911.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1865_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/bjd.18622","volume":"183","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Griffiths CEM, Williams HC, Andersen YMF, Thyssen JP. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. Br J Dermatol. 2020;183(1):128\u201338.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1865_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00403-021-02321-z","volume":"315","author":"LEM de Wijs","year":"2023","unstructured":"de Wijs LEM, van Egmond S, Devillers ACA, Nijsten T, Hijnen D, Lugtenberg M. Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study. Arch Dermatol Res. 2023;315(1):75\u201383.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1865_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index\u2014a practical guide. Dermatitis. 2022;33(3):187\u201392.","journal-title":"Dermatitis"},{"issue":"12","key":"1865_CR19","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1007\/s13555-022-00836-5","volume":"12","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Simpson EL, Calimlim BM, et al. Determining severity strata for three atopic dermatitis patient-reported outcome questionnaires: defining severity score ranges for the worst pruritus numerical rating scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS). Dermatol Ther (Heidelb). 2022;12(12):2817\u201327.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1865_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1865_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology (Basel). 2015;230(1):27\u201333.","journal-title":"Dermatology (Basel)"},{"issue":"12","key":"1865_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1865_CR23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326\u201332.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01865-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:15Z","timestamp":1788981675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01865-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01865-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jonathan I. Silverberg: Has received honoraria as a consultant and\/or advisory board member for AbbVie, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, Eli Lilly, FIDE, Galderma, GlaxoSmithKline, Incyte, Inmagene, Invea, Kiniksa, LEO Pharma, Merck, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sandoz, Sanofi Genzyme, Shaperon, TARGET-RWE, Teva, Triveni, Union, and UpToDate; speaker for AbbVie, Arcutis, Dermavant, Eli Lilly, Galderma, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme; institution received grants from Galderma, Incyte, and Pfizer. Vimal H. Prajapati: Advisor, consultant, and\/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP\/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, CorEvitas, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, Janssen, Johnson & Johnson, Johnson & Johnson Innovative Medicine, Kenvue, LEO Pharma, Medexus, Novartis, Organon, Paladin, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharmaceuticals, Tribute, and UCB; investigator for: AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, Johnson & Johnson Innovative Medicine, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, UCB, and Vyne Therapeutics; received grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Susanne Abraham: Susanne Abraham\u00a0has served as a consultant, lecturer, researcher, and\/or has received research grants from AbbVie, Amgen, BMS, Beiersdorf, Janssen, LEO Pharma, Lilly,\u00a0Novartis, Pfizer, Sanofi, Takeda, and UCB. Alan D. Irvine: Is a consultant and\/or speaker for AbbVie, Arena, BenevolentAI, Chugai Pharma, Eli Lilly, Genentech, Janssen, Novartis, Regeneron, Sanofi Genzyme, and Pfizer. Melinda J. Gooderham: Has served as an advisor, speaker, and\/or consultant for AbbVie, Akros Pharma Inc., Amgen, Arena, Arcutis, Asana BioSciences, AnaptysBio, Aristea, Bausch Health, Boehringer Ingelheim International, Bristol Myers Squibb, Celgene, Coherus Biosciences, Dermavant, Dermira, Eli Lilly, Galderma SA., GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Meiji, Moonlake, Novartis, Nimbus Therapeutics, Pfizer, Regeneron, Reistone, Sanofi Genzyme, Sun Pharmaceuticals, and UCB; and support for attending meetings from AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Pfizer, Sanofi Genzyme, and UCB. Emma Guttman-Yassky: Employee of Mount Sinai and has received research funds (grants paid to her institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana BioSciences, AstraZeneca, Boehringer Ingelheim, Cara Therapeutics, Celgene, Eli Lilly, Galderma, Glenmark\/Ichnos Sciences, Innovaderm, Janssen, KAO, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron, and UCB; is a consultant for AbbVie, Almirall, Amgen, Arena, Asana BioSciences, Aslan, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, LEO Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB, and Ventyx Biosciences. Hideaki Tanizaki: Has received honoraria from AbbVie, Eli Lilly, Janssen, Kyowa Kirin, Maruho, Sanofi, Sun Pharmaceuticals, and Torii; has received contract research and collaborative research funding from Maruho and Sun Pharmaceuticals; has received scholarship donations from Maruho, Sun Pharmaceuticals, and Torii. Marius Rademaker: Investigator at AbbVie, Akesio, Aslan, Boehringer Ingelheim, Botanix, Douglas, Galderma, Hexima, and Suzhou Connect. Kilian Eyerich: Has received grants and honoraria from, and has served as a speaker, investigator, consultant and\/or advisor for AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Galderma, Hexal, Janssen, Novartis, Pfizer, Sanofi, and UCB. Alvaro Moreira, Wan-Ju Lee: Current or former employees of AbbVie who may hold stock and\/or stock options in the company. Richard Ta: Is a contractor of AbbVie. Shirley H. Chen: Is a full-time, salaried employee of Tigermed-BDM Inc., which provided statistical analysis support that was funded by AbbVie.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The independent ethics committee or institutional review board at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment. The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent to participate in the study and for publication before screening.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}